Editas Medicine Inc (EDIT)

NASDAQ HEALTHCARE
$2.91 -9.35% RSI 50 Neutral Add Alert

Moving Averages

SMA 200
$2.59
Price above

Company Profile

Editas Medicine, Inc., a clinical-stage genome editing company, is focused on developing transformative genomic drugs to treat a variety of serious diseases. The company is headquartered in Cambridge, Massachusetts.

Sector
HEALTHCARE
Industry
BIOTECHNOLOGY
Market Cap
$282.85M
P/E Ratio
None
EPS
$-1.8
Beta
2.042
Dividend Yield
0.00%
52-Week High
$4.537
52-Week Low
$1.18

Similar stocks in BIOTECHNOLOGY

BNTX
BioNTech SE
RSI 62.0
VRTX
Vertex Pharmaceuticals Inc
RSI 40.0
CRSP
CRISPR Therapeutics AG
RSI 41.0
MRNA
Moderna Inc
RSI 46.0
VKTX
Viking Therapeutics Inc
RSI 44.0
SRPT
Sarepta Therapeutics Inc
RSI 48.0

Data last updated: April 11, 2026 at 12:12 AM EDT

Track EDIT for free

Get e-mail RSI alerts when Editas Medicine Inc enters oversold or overbought territory. Free forever.

Add Alert